Glecirasib Citrate Application Scope

Indication: Treatment of adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring KRAS G12C mutation after prior systemic therapy.

Glecirasib Citrate Characteristics

Ingredients: Glecirasib citrate, a selective covalent KRAS G12C inhibitor.
Properties: Oral small-molecule, highly selective, irreversibly binds KRAS G12C, blocks downstream MAPK pathway, favorable safety and tolerability.
Packaging Specification: Tablets, 800 mg daily dosing; commercial packaging per box.
Storage: Store in a cool, dry place, protected from light.
Expiry Date: See package insert.
Executive Standard: Internal pharmaceutical standard.
Approval Number: National drug approval number available on label.
Date of Revision: See latest package insert.
Manufacturer: Jacobio Pharma / Shanghai Allist Pharmaceuticals Co., Ltd.

Guidelines for the Use of Airuikai

Dosage and Administration:
- Recommended Dose: 800 mg orally once daily until disease progression or unacceptable toxicity.
- Administration: Swallow tablets whole with water, with or without food.
- Missed Dose: If a dose is missed, take as soon as possible on the same day; do not double the next dose.
Adverse Reactions:
- Common Adverse Reactions:
  - Nausea
  - vomiting
  - fatigue
  - mild anemia
  - transient liver enzyme elevation
  - hypertriglyceridemia
- Serious Adverse Reactions:
  - Grade 3-4 hepatic enzyme elevation
  - severe hematologic toxicity
  - treatment discontinuation in rare cases
Contraindications:
- Hypersensitivity to glecirasib or any excipients.
- Severe hepatic impairment unless benefits outweigh risks.
Precautions:
- Confirm KRAS G12C mutation before starting treatment.
- Monitor liver function, blood counts, and biochemical parameters regularly.
- Consider dose reduction or discontinuation for severe adverse events.

Glecirasib Citrate Interactions

No major CYP-mediated interactions reported.
Combination with other targeted therapies (e.g., SHP2 or EGFR inhibitors) under investigation.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.